Abstract | OBJECTIVE: DESIGN: METHOD: RESULTS: The search produced 6 case reports, 5 patient series, 3 pilot studies, 2 open-label studies and 1 RCT concerning the use of TCIs for the treatment of vulvar lichen sclerosus. The literature shows that both medications are effective and well tolerated. However, glucocorticoids seem to be effective in more patients than TCIs. Tacrolimus has a stronger immunosuppressant effect than pimecrolimus and therefore seems to be more effective without having more observed side-effects. CONCLUSIONS: TCIs may represent a useful second-line therapeutic option for patients for whom treatment with glucocorticoids is not effective or who do not tolerate them well. Randomized clinical studies are required to determine the role of TCIs in the treatment of lichen sclerosus. CONFLICT OF INTEREST: none declared. Financial support: none declared.
|
Authors | Marloes S Maassen, Helena C van Doorn |
Journal | Nederlands tijdschrift voor geneeskunde
(Ned Tijdschr Geneeskd)
Vol. 156
Issue 36
Pg. A3908
( 2012)
ISSN: 1876-8784 [Electronic] Netherlands |
Vernacular Title | Lokale behandeling met calcineurine-remmers voor vulvaire lichen sclerosus. |
PMID | 22951124
(Publication Type: English Abstract, Journal Article, Meta-Analysis, Review)
|
Chemical References |
- Calcineurin Inhibitors
- Glucocorticoids
- Immunosuppressive Agents
- Calcineurin
|
Topics |
- Administration, Cutaneous
- Administration, Topical
- Calcineurin
(adverse effects, therapeutic use)
- Calcineurin Inhibitors
- Female
- Glucocorticoids
(adverse effects, therapeutic use)
- Humans
- Immunosuppressive Agents
(adverse effects, therapeutic use)
- Treatment Outcome
- Vulvar Lichen Sclerosus
(drug therapy)
|